Big pharma drives innovation in pain therapy development

imagessef

(Photo Courtesy: www.carrollmzoe.soup.io)

Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8 percent, as limited understanding of pain pathophysiology continues to hinder drug development in this arena, says business intelligence provider GBI Research.

The company's latest report states that patent applications for pain treatments between 2008 and 2012 were dominated by big pharma, including Sanofi, Novartis and Merck, which submitted 169, 162 and 142 applications, respectively.

However, the global pain treatment market is dominated by opioids and steroidal anti-inflammatory drugs, with no novel products currently able to challenge these products' efficacy in treating moderate to severe acute pain.

Furthermore, despite the significant unmet needs for more effective therapies in other pain subtypes, such as chronic and neuropathic pain, due to their rising prevalence, the factors underpinning these subtypes are complex and poorly understood.

However, this limited knowledge is being countered by technological advances and significant research efforts, with new insights translating into an expanding pool of novel therapeutic targets.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X